Paratek Pharmaceuticals (NASDAQ:PRTK) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) in a research report released on Thursday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Paratek Pharmaceuticals Price Performance

Shares of PRTK opened at $1.54 on Thursday. The company has a 50-day moving average of $2.00 and a two-hundred day moving average of $2.29. The stock has a market cap of $85.55 million, a price-to-earnings ratio of -1.31 and a beta of 1.52. Paratek Pharmaceuticals has a one year low of $1.29 and a one year high of $3.65.

Insider Buying and Selling

In other Paratek Pharmaceuticals news, Chairman Michael Bigham sold 15,750 shares of the business’s stock in a transaction on Wednesday, December 21st. The shares were sold at an average price of $1.99, for a total transaction of $31,342.50. Following the sale, the chairman now directly owns 1,209,702 shares of the company’s stock, valued at approximately $2,407,306.98. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Evan Loh sold 23,489 shares of the company’s stock in a transaction dated Wednesday, December 21st. The stock was sold at an average price of $1.99, for a total value of $46,743.11. Following the transaction, the chief executive officer now owns 1,208,198 shares in the company, valued at approximately $2,404,314.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Michael Bigham sold 15,750 shares of the firm’s stock in a transaction that occurred on Wednesday, December 21st. The stock was sold at an average price of $1.99, for a total transaction of $31,342.50. Following the sale, the chairman now owns 1,209,702 shares of the company’s stock, valued at $2,407,306.98. The disclosure for this sale can be found here. In the last 90 days, insiders sold 59,996 shares of company stock valued at $118,762. Company insiders own 8.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Natixis acquired a new stake in shares of Paratek Pharmaceuticals during the 4th quarter valued at $54,000. AIGH Capital Management LLC boosted its position in Paratek Pharmaceuticals by 6.9% during the fourth quarter. AIGH Capital Management LLC now owns 4,156,891 shares of the specialty pharmaceutical company’s stock valued at $7,773,000 after purchasing an additional 269,719 shares during the last quarter. CI Private Wealth LLC purchased a new position in Paratek Pharmaceuticals in the fourth quarter valued at about $29,000. Mackenzie Financial Corp acquired a new position in Paratek Pharmaceuticals in the 4th quarter worth about $41,000. Finally, Millennium Management LLC increased its position in Paratek Pharmaceuticals by 93.3% in the 4th quarter. Millennium Management LLC now owns 568,568 shares of the specialty pharmaceutical company’s stock worth $1,063,000 after purchasing an additional 274,469 shares during the last quarter. Institutional investors and hedge funds own 41.90% of the company’s stock.

Paratek Pharmaceuticals Company Profile

(Get Rating)

Paratek Pharmaceuticals, Inc engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections.